The most comprehensive and go-to place for all short selling reseach reports online.
Currently a total of 275 research reports from 14 investment research firms has been aggregated, with new reports being added and updated constantly
Current Share Price: 1.890 
Hindenburg Research
Initial Report Date(2017/11/17)Share Price:4.800  
OPKO Health: A House Of Cards Tumbling In The Dark
 Details Link >
Opko has dropped approximately 25% since its recent quarterly report issued last Wednesday after it missed estimates on both revenue and earnings. In addition to the continued disappointing sales in the company’s FDA-approved product Rayaldee, the diagnostics division also saw a significant drop in revenue. We believe the recent quarter is merely the beginning of a series of continuing problems at the company.
By wantattse 
Subsequent Report (2018/02/27)Share Price:3.700  
OPKO Health: New Signs Of Chaos In Key Diagnostics Division
 Details Link >
The President of OPKO’s key BioReference division (82.8% of 2016 revenue) resigned, and no new successor was named. We believe this to be a strong negative omen. A recent lawsuit filed against BioReference alleges violations of law, including forgery, releasing unverified test results, and falsification of employee training and competency documents. A pattern of lawsuits emerges naming BioReference in four New York insurance fraud cases. OPKO’s recently FDA approved Varubi (licensed to TESARO) recently updated its risk factors to include major side effects, potentially inhibiting yet another cash flow stream. With tangible book value of only about $10.5 million (i.e.: 2 cents per share) and with very few bright spots to point to, we see significant further downside for OPKO.
By wantattse 
Subsequent Report (2018/09/11)Share Price:3.900  
Opko Health: If These SEC Charges Were Surprising Then You Haven’t Been Paying Attention
 Details Link >
Opko’s stock is now halted following SEC charges alleging fraud by both the company and its Chairman & CEO Phil Frost. The company put out a rather impotent statement Friday evening claiming the SEC complaint “contains serious factual inaccuracies” without identifying a single factual inaccuracy. We anticipate that criminal charges could follow given the reported FBI investigation that parallels the SEC charges. Frost is Opko’s key leader, key lender, and its largest holder with over 30% of the equity, leaving the company in a perilous position. Opko’s business was already in tatters. It is bleeding cash, has negative tangible equity, and a weak pipeline. We do not see a bottom for this stock. Price target zero.
By wantattse 
QTsky is a question & task based crowdsourcing research platform - you can post any research need - whether it's a simple question or a complex task - and find the right industry expert or software engineer to help you obtain the right answer or solution. And you only pay on a per-question or per-task basis after your QT is completed

QTsky.com and all of its information providers will not be liable for any errors,omissions,delays or interruptions in all the information and data on the QTsky.com website or for any damages relating to your use of the information provided herein. All data,research findings,opinions and information herein, whether provided by QTsky.com or by its users,should not be treated as professional investment advice.